Merck & Co Inc

MRK

$78.00

+4.1% (1 year change)

Avg closing price

Price range

Market Cap

$197 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$71.09 - $85.73

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

27.85x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$2.49 (3.2%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $197 Billion
Enterprise Value $221 Billion
Dividend Yield $2.49 (3.2%)
1 Year Return +7.3%
52-Week High $85.73
52-Week Low $71.09
Beta 0.54
Outstanding Shares 2.53 Billion
Avg 30 Day Volume 11.5 Million

Valuation

P/E Ratio 27.85
PEG -14.74
Earnings per Share $2.78
Price to Sales Ratio 4.33
Price to Book Ratio 7.8
Revenue to Enterprise Value 4.66
EBIT to Enterprise Value 29.0
Total Debt to Enterprise Value 0.14
Debt to Equity 1.26

Profitability

Revenue $47.3 Billion
Gross Profit $31.6 Billion
EBIT $7.61 Billion
Net Income $6.48 Billion
Profit Margin 13.7%
Quarterly Earnings Growth (YoY) -188.9%
Return on Equity 25.61%
Return on Assets 7.08%
Return on Invested Capital 11.83%

News

Germany's Merck sees boost from labs supplies earnings

Germany's Merck sees boost from labs supplies earnings

https://www.investing.com/news/stock-market-news/germanys-merck-sees-boost-from-labs-supplies-earnings-2503455

Investing.com Investing.com, 2 days ago
UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer

UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer

England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE ) and Merck KGaA’s (OTCMKTS: MKGAF) Bavencio (avelumab) as first-line maintenance therapy for urothelial cancer after...

Benzinga Benzinga, 3 days ago
Global Vaccines Market Analysis & Forecasts, 2017-2020 & 2021-2025 - Company Value by AstraZeneca, GSK, Johnson & Johnson, Merck & Co, Moderna, Novavax, Pfizer, & Sanofi Pasteur

Global Vaccines Market Analysis & Forecasts, 2017-2020 & 2021-2025 - Company Value by AstraZeneca, GSK, Johnson & Johnson, Merck & Co, Moderna, Novavax, Pfizer, & Sanofi Pasteur

DUBLIN , May 6, 2021 /PRNewswire/ -- The "Vaccines Market - Global Industry Analysis (2017 - 2020), Growth Trends and Market Forecast (2021 - 2025)" report has been added to ResearchAndMarkets.com'...

Benzinga Benzinga, 7 days ago